Mortality risk prediction for primary appendiceal cancer

Winicki, Nolan M.; Radomski, Shannon N.; Ciftci, Yusuf; Sabit, Ahmed H.; Johnston, Fabian M.; Greer, Jonathan B.

doi:10.1016/j.surg.2024.02.014

Cited by 1 publication

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low grade neuroendocrine tumors, not addressed by this guideline, have the best prognosis; of non-metastatic epithelial tumors, the most recent studies report five-year overall survival of 63-75% for well-and moderately-differentiated mucinous disease, and 60-70% for nonmucinous. 1,3,14,17,18,[20][21][22][23] Data on non-metastatic, higher-grade tumors is scant as they often present at more advanced stages.…”

Section: Introductionmentioning

confidence: 99%

Consensus guideline for the management of patients with appendiceal tumors Part 1: Appendiceal tumors without peritoneal involvement

Turaga

2024

Preprint

View full text Add to dashboard Cite

Background: Appendiceal tumors comprise a heterogeneous group of tumors which may be localized or disseminate throughout the peritoneum. Limited high quality clinical data exists and many practices have been extrapolated from colorectal cancer without validation in appendiceal cohorts. Many controversies exist regarding their treatment, and practices vary widely between centers and care settings. A national consensus update of best management practices for appendiceal malignancies was performed to better standardize care. Methods The 2018 Chicago consensus guideline was updated via modified Delphi consensus, performed over two rounds using nationally circulated surveys. Supporting evidence was evaluated using rapid systematic reviews. Key systemic therapy concepts were summarized by content experts. Results Most supporting literature consists of observational studies, but increasingly high-quality studies are becoming available to drive management. Two consensus-based pathways were generated for localized appendiceal tumors, one for epithelial mucinous neoplasms and another for appendiceal adenocarcinoma. Of 138 participants responding in the first round, 133 (96%) engaged in the second round. Over 90% consensus was achieved for all pathway blocks. Key points include minimizing intervention invasiveness where permitted by pathologic classification and margin status, and determining what margin and pathologic findings are indications for consideration of cytoreduction with or without intraperitoneal chemotherapy. Surveillance and systemic therapy recommendations are also presented. Conclusion With growing but still primarily observational evidence currently dictating care, these consensus recommendations provide expert guidance in the treatment of appendiceal tumors without peritoneal involvement.

show abstract

Section: Introductionmentioning

confidence: 99%

Consensus guideline for the management of patients with appendiceal tumors Part 1: Appendiceal tumors without peritoneal involvement

Turaga

2024

Preprint

View full text Add to dashboard Cite

show abstract

Mortality risk prediction for primary appendiceal cancer

Cited by 1 publication

References 33 publications

Consensus guideline for the management of patients with appendiceal tumors Part 1: Appendiceal tumors without peritoneal involvement

Consensus guideline for the management of patients with appendiceal tumors Part 1: Appendiceal tumors without peritoneal involvement

Contact Info

Product

Resources

About